Literature DB >> 1382173

Immunocytochemical detection of factor XIII A--subunit in acute leukemia.

R Invernizzi1, P De Fazio, A M Iannone, L M Zambelli, M P Rastaldi, G Ippoliti, E Ascari.   

Abstract

Factor XIII (FXIII) is a plasma pro-transglutaminase consisting of A and B subunits in a tetrameric structure. A cellular form of FXIII consisting exclusively of A subunits exists in platelets and monocytes: monocyte FXIII may be involved in connective tissue organization. To evaluate the expression and diagnostic significance of FXIII A subunit (FXIIIA) in acute leukemia, we performed an immunocytochemical study (PAP technique) with rabbit antiserum against FXIIIA on leukemic blasts of 48 cases. FXIIIA was detected only in myelomonocytic (M4), monocytic (M5) and megakaryocytic (M7) cases: in M4 and M5 samples the amount of blast cytoplasmic FXIIIA was closely correlated with the expression of monocyte-specific antigenic and cytochemical markers. Our data show immunocytochemical detection of FXIIIA to be useful for acute leukemia characterization.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1382173     DOI: 10.1016/0145-2126(92)90163-2

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  2 in total

1.  Expression of Coagulation Factor XIII Subunit A Correlates with Outcome in Childhood Acute Lymphoblastic Leukemia.

Authors:  Bettina Kárai; Zsuzsanna Hevessy; Eszter Szánthó; László Csáthy; Anikó Ujfalusi; Katalin Gyurina; István Szegedi; János Kappelmayer; Csongor Kiss
Journal:  Pathol Oncol Res       Date:  2017-05-18       Impact factor: 3.201

2.  Coagulation FXIII-A Protein Expression Defines Three Novel Sub-populations in Pediatric B-Cell Progenitor Acute Lymphoblastic Leukemia Characterized by Distinct Gene Expression Signatures.

Authors:  Katalin Gyurina; Bettina Kárai; Anikó Ujfalusi; Zsuzsanna Hevessy; Gábor Barna; Pál Jáksó; Gyöngyi Pálfi-Mészáros; Szilárd Póliska; Beáta Scholtz; János Kappelmayer; Gábor Zahuczky; Csongor Kiss
Journal:  Front Oncol       Date:  2019-10-25       Impact factor: 6.244

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.